Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Connect Biopharma Holdings Ltd (CNTB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CNTB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.1% | Avg. Invested days 12 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 55.56M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 2 | Beta -0.27 | 52 Weeks Range 0.51 - 1.60 | Updated Date 06/30/2025 |
52 Weeks Range 0.51 - 1.60 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -66.1% | Operating Margin (TTM) -81.69% |
Management Effectiveness
Return on Assets (TTM) -12.47% | Return on Equity (TTM) -18.66% |
Valuation
Trailing PE - | Forward PE 0.77 | Enterprise Value -27493944 | Price to Sales(TTM) 2.13 |
Enterprise Value -27493944 | Price to Sales(TTM) 2.13 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.19 | Shares Outstanding 55561100 | Shares Floating 14373645 |
Shares Outstanding 55561100 | Shares Floating 14373645 | ||
Percent Insiders 40.65 | Percent Institutions 43.97 |
Analyst Ratings
Rating 2 | Target Price 6.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Connect Biopharma Holdings Ltd
Company Overview
History and Background
Connect Biopharma Holdings Ltd. is a global clinical-stage biopharmaceutical company dedicated to developing therapies for chronic inflammatory diseases. Founded in 2012, it has focused on creating and advancing a pipeline of novel molecules targeting key pathways in immune-mediated disorders. The company went public but was taken private in 2023.
Core Business Areas
- Drug Development: Researching, developing, and clinically testing novel therapeutic candidates for chronic inflammatory diseases.
- Commercialization: Preparing for the potential commercialization of its drug candidates, pending regulatory approval.
Leadership and Structure
Details about their executive team are not readily available due to its private status. Organizational structure information is similarly limited, reflecting its current stage as a research-driven company.
Top Products and Market Share
Key Offerings
- CBP-201 (Itezolumab): A monoclonal antibody targeting IL-17 receptor A (IL-17RA), being developed for atopic dermatitis (AD) and asthma. Clinical trials are ongoing. Market share information is not publicly available due to its pre-commercialization status. Competitors include Sanofi (SNY) with Dupixent, and AbbVie (ABBV) with Rinvoq.
- CBP-174: An oral peripherally acting antagonist of histamine receptor 3 (H3R) being developed for pruritus. Clinical trials are ongoing. Market share information is not publicly available. Competitors include Kiniksa Pharmaceuticals, and other pharmaceutical companies developing pruritus treatments.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on chronic inflammatory diseases, is characterized by high growth potential driven by the increasing prevalence of these conditions and advancements in immunology and targeted therapies. Competition is intense, with numerous companies vying to develop novel treatments.
Positioning
Connect Biopharma positions itself as an innovator in the field of inflammatory diseases, focusing on differentiated mechanisms of action and unmet medical needs. Its competitive advantage lies in its pipeline of novel molecules and its experienced management team.
Total Addressable Market (TAM)
The TAM for atopic dermatitis and asthma is estimated to be in the tens of billions of dollars. Connect Biopharma aims to capture a significant share of this market with its lead drug candidate, CBP-201, if approved.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting validated pathways
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
- Dependence on successful clinical trial outcomes
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or in-licensing
- Regulatory approvals for its drug candidates
Threats
- Competition from existing and emerging therapies
- Clinical trial failures
- Regulatory hurdles
- Pricing pressures
Competitors and Market Share
Key Competitors
- SNY
- ABBV
- LLY
- MRK
- BMY
- PFE
Competitive Landscape
Connect Biopharma faces intense competition from established pharmaceutical companies with approved therapies and robust pipelines. Its success depends on demonstrating superior efficacy and safety of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of its pipeline through preclinical and clinical development stages.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals for its drug candidates. Potential revenue streams from commercialization or partnerships could drive future growth.
Recent Initiatives: Recent initiatives include advancing CBP-201 and CBP-174 through clinical trials and exploring potential partnerships.
Summary
Connect Biopharma is a development-stage company with a promising pipeline of novel therapeutics for inflammatory diseases. While it faces significant challenges including competition and regulatory hurdles, its innovative approach and experienced team position it for potential success. Successful clinical trials and strategic partnerships are crucial for future growth and realizing value. With its current private ownership, it needs to focus on proving its pipeline's value to drive long term performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- ClinicalTrials.gov
- Analyst Reports (where available, limited due to private status)
- SEC Filings (historical prior to going private)
Disclaimers:
The information provided is based on publicly available data and analyst estimates. Accuracy is not guaranteed. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Connect Biopharma Holdings Ltd
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-03-19 | CEO & Director Dr. Barry D. Quart Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 62 | Website https://www.connectbiopharm.com |
Full time employees 62 | Website https://www.connectbiopharm.com | ||
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.